codexis.com - CDXS Forward P/S Multiple
Codexis, Inc. (CDXS) relies on moderately stable cash flows from contract work and licenses. Synergy with global pharma behemoths via CodeEvolver accelerates the creation of unique enzymes, while a mature product portfolio optimizes drug synthesis. The forward P/S trend visualizes market revenue expectations, where 1.40 serves as the current metric level, capturing the balance between capitalization and future earnings.
codexis.com - analytical breakdowns and key metrics (CDXS)
- market price and analyst price targets:
- issuer market value details:
- issuer book value statistics:
- debt level and financial liquidity data:
- net income and valuation multiples indicators:
CDXS - Company Profit|Projected Future Earnings Codexis, Inc.|CDXS - P/E Multiple|Forward P/E Multiple Codexis|CDXS - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization CDXS|CDXS - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Codexis, Inc.|CDXS - Earnings per share for the last 12 months|Quarterly EPS earnings growth codexis.com|CDXS - Earnings per share growth rate in current year|Expected earnings per share growth for next year Codexis, Inc.
- sales volume and revenue indicators:
Fundamental company valuation:CDXS (Codexis Bio)
High switching costs for Codexis, Inc. (CDXS) customers, driven by patent protection of DNA technologies, justify the market's premium revenue expectations. Analyzing the forward price-to-sales ratio, an investor assesses current capitalization by discounting future flows at the WACC rate, where extreme values on the chart signal either an overpayment for the asset or a deep discount in the event of business model degradation.
Analysis of competing companies
Price-to-Projected Revenue Ratio Tempus AI, Inc. TEM|QGEN: Market Cap to Projected Revenue|Ionis Pharma - Forward P/S Multiple|Repligen Inc. (RGEN) - Forward Price-to-Revenue Multiple|RNA (Avidity Biosciences) - Forward Price-to-Revenue Multiple|CRSP - Market Cap to Expected Sales Ratio|WGS (GeneDx) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Ultragenyx Pharmaceutical Inc. (RARE)|Forward P/S Multiple BEAM|Sarepta Corp - Market Cap to Projected Revenue|Twist Bioscience - Forward Price-to-Revenue Multiple|TXG: Market Cap to Projected Revenue|NTLA - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Stoke Therapeutics Inc STOK|BLFS: Forward P/S Multiple|Market Cap to Projected Revenue WVE|Price-to-Projected Revenue Ratio Maze Therapeutics Inc|Market Cap to Projected Revenue SION (sionnatx.com)|Forward P/S Multiple PRME|Forward P/S Multiple Taysha Gene Therapies Inc (TSHA)|Forward P/S Multiple QURE (uniQure Corp)|MGTX - Forward Price-to-Revenue Multiple|RGNX - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio solidbio.com|OCGN: Forward P/S Multiple|Market Cap to Projected Revenue PACB|BNTC (Benitec) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Design Corp DSGN|Forward Price-to-Revenue Multiple RCKT (Rocket Pharmaceuticals)|4dmoleculartherapeutics.com - Market Cap to Projected Revenue|Forward P/S Multiple LXEO (Lexeo Therapeutics, Inc.)|Market Cap to Expected Sales Ratio Korro Bio Inc. (KRRO)|EDIT - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio Silence Therapeutics Corp SLN|PRQR (proqr.com) - Forward Price-to-Revenue Multiple|sangamo.com - Forward Price to Sales|NAUT (Nautilus Biotechnology, Inc.) - Forward P/S Multiple|Metagenomi Inc. (MGX) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Precision BioSciences, Inc. (DTIL)|generationbio.com - Market Cap to Projected Revenue|Forward P/S Multiple BOLD (Boundless Bio, Inc.)|XCUR - Forward Price-to-Revenue Multiple|IMNN: Forward Price-to-Revenue Multiple|Market Cap to Expected Sales Ratio Phio Pharmaceuticals PHIO|MBIO: Forward P/S Multiple|Forward Price-to-Revenue Multiple TransCode Therapeutics, Inc.|BNGO (Bionano Genomics Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue APDN (adnas.com)|Forward Price-to-Revenue Multiple BLUE (bluebird bio)|immunoprecise.com - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega OMGA|Market Cap to Expected Sales Ratio Singular Genomics Corp (OMIC)|Regulus Therapeutics - Forward P/S Multiple|SYRS (syros.com) - Market Cap to Projected Revenue|Telesis Bio (TBIO) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TCON|UBX (Unity Bio) - Forward P/S Multiple
